BioSpace News Archive

Vicarious Surgical Inc. announced it will effect a 1-for-30 reverse stock split of the Company’s issued and outstanding Class A common stock, par value $0.0001 per share, and Class B common stock, par value $0.0001 per share.

Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Iqirvo® (elafibranor) 80 mg tablets for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.

4Moving Biotech, a spin-off of 4P-Pharma committed to developing first-in-class treatments to modify the natural course of knee osteoarthritis, announces the successful achievement of the Phase 1 Lasare trial in knee osteoarthritis patients using 4P004.

Almirall, a global pharmaceutical company dedicated to medical dermatology, announced that the U.S. Food and Drug Administration has approved Almirall’s recent supplemental New Drug Application to expand the use area for its drug, Klisyri, to up to 100 cm2.

Flamingo Therapeutics announced a poster presentation on FLM-7523 at the Annual Congress of the European Association for Cancer Research 2024 Congress, being held in Rotterdam, Netherlands from June 10-13, 2024.

Diakonos Oncology Corporation, a clinical stage immuno-oncology company, announced that it will present at the Emerging Growth Conference on Wednesday, June 12.

Apellis Pharmaceuticals, Inc. announced that SYFOVRE® preserved visual function at 36 months in patients with geographic atrophy secondary to age-related macular degeneration.

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, announced that it received an approval from the Institutional Review Board of Rabin Medical Center, a leading medical institution in Israel where the study will be conducted.

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”) today announced that it entered into a collaboration agreement with SIGA Technologies (Nasdaq: SIGA) in the first quarter of 2024, to support the development of Calidi’s systemic and targeted RTNova (CLD-400) virotherapy platform, which has the potential to provide a universal treatment for all tumor types.